Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

What Semax actually costs in the US

Zero official US Semax prices were found. FDA records show only unfinished bulk powders, and Medicaid's 2026 NADAC file has no matching price.

Why we wrote this. US Semax price pages often mix bulk listings, seller asks and assumed monthly use. This article checks official product and acquisition-cost records instead.

In this article (10 sections)
  1. TL;DR
  2. The approval inventories produced no product to price
  3. What the NDC records contain
  4. The Medicaid price file had zero Semax matches
  5. Cash price and insurance price are both unresolved
  6. A compounded quote would be a different price category
  7. Why online prices are excluded
  8. There is no defensible monthly Semax cost
  9. How to verify a future US price claim
  10. Medical and regulatory disclaimers

We found zero official US finished-product prices for Semax. FDA's Drugs@FDA data and the current Orange Book contained no Semax product under the names checked on 16 November 2026[1][2]. The 2026 Medicaid NADAC file also contained no Semax price record[5]. This does not mean Semax costs zero dollars. It means there is no identified FDA-approved Semax pack with an official US product price to report.

The National Drug Code directory does show eight Semax records, but all eight are unfinished bulk-ingredient powders. They are not nasal sprays, injectable vials or retail prescription packs. FDA says an NDC listing does not denote approval or establish reimbursement eligibility. Those records contain package quantities, not prices, so they cannot be converted into a consumer cash cost.

For background on the molecule, read the Semax overview. The United States regulation hub explains the wider approval system. Border questions belong in the US Semax import guide. This article applies a narrower test: does a defined finished product have a public, comparable US price? The official records do not identify one.

TL;DR

As of 16 November 2026, we found no FDA-approved Semax product and no Semax entry in the 2026 NADAC acquisition-cost file. The NDC directory listed eight unfinished bulk powders but no finished product and no price. There is therefore no verified US list price, official cash pack price, standard Medicaid acquisition cost or evidence-based monthly cost to quote. Online seller amounts and clinic bundles are excluded because they do not establish an approved, comparable finished medicine.

The approval inventories produced no product to price

Drugs@FDA is FDA's application-based database for approved drug products. Its downloadable data, updated 13 November 2026, contained no match for Semax, Semax acetate or the identity variants checked[1]. An exact openFDA Drugs@FDA query for Semax also returned 'No matches found.' We used the downloadable FDA page as the citation because it is the stable official source for the searched files.

We checked the Orange Book separately. Its products, patent and exclusivity files contained zero matches for Semax, Semax acetate, ACTH (4-7), ACTH(4-7), Pro-Gly-Pro, Pro Gly Pro, Met-Glu-His-Phe-Pro-Gly-Pro and MEHFPGP[2]. The Orange Book describes approved drug products and their application details. A zero result under those names is a bounded database finding, not a claim about confidential applications or every possible spelling.

These searches matter because a meaningful medicine price needs a defined product. At minimum, that means a finished dosage form, strength, package quantity and date. No approved Semax record supplied those fields. A foreign product, analytical standard or seller-created spray does not acquire a US list price merely because its label uses the same peptide name.

What the NDC records contain

FDA's NDC directory covers more than approved medicines. FDA says it includes submitted listing data for finished and unfinished drugs, including approved and unapproved products[3]. The Semax API query returned eight records in data last updated 13 November 2026[4]. Every record had finished set to false, product type BULK INGREDIENT and dosage form POWDER.

The records reported containers ranging from 0.1 grams to 5,000 grams. Some marketing categories read BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING, while others read BULK INGREDIENT. These are labeler-submitted classifications for unfinished material. They do not identify a dispensed nasal spray, a patient vial or any other finished retail pack.

FDA warns that NDC inclusion does not mean the agency verified the submitted information. Assignment of a number does not denote approval, and listing does not establish Medicare, Medicaid or other reimbursement eligibility[3]. A bulk package quantity is therefore not a medicine price. Dividing an unknown ingredient cost by an assumed dose would add both an unsupported price and self-directed dosing assumptions.

The Medicaid price file had zero Semax matches

CMS publishes National Average Drug Acquisition Cost data through Medicaid.gov. NADAC is a weekly reference dataset for retail community pharmacy acquisition costs. The current 2026 CSV available on 16 November was dated 11 November 2026 and contained 1,358,735 rows[5].

We searched the NDC description and every other field for the same identity variants used in the approval checks. Semax, Semax acetate, ACTH (4-7), ACTH(4-7), Pro-Gly-Pro, Pro Gly Pro, Met-Glu-His-Phe-Pro-Gly-Pro and MEHFPGP each returned zero rows. No NADAC per-unit amount, pricing unit, effective date or corresponding generic amount was available for Semax.

NADAC absence has a specific meaning. The inspected acquisition-cost file supplied no Semax price record. This is not proof that no private payer has ever handled an exceptional claim, nor is NADAC a census of cash transactions. The file cannot create a price for unfinished powders. The safe conclusion is zero official finished-product prices found, not a zero-dollar price.

Cash price and insurance price are both unresolved

A cash price normally attaches to a named finished product and pack sold through a lawful dispensing route. The approval and pricing files identified no such Semax pack. We therefore cannot report an official cash amount, compare pharmacy discounts or calculate a normal retail range. A coupon page would not solve the missing product identity even if one happened to display the name.

The same boundary applies to insurance. No approved Semax product or NADAC record was found, and the NDC directory itself says listing does not establish payer eligibility. That does not justify a universal claim that every conceivable patient-specific expense is excluded under every plan. It does mean we found no standard official reimbursement amount or ordinary product record on which to base a coverage estimate.

General deductibles, copays and Medicaid rules are not Semax prices. Applying them here would assume that a covered prescription item exists. The official product checks did not identify one. Readers with a specific claim question need the exact product, dispensing pharmacy and written plan decision rather than a generic benefits number.

A compounded quote would be a different price category

A pharmacy quote, if one were lawfully made for an identified patient and product, would cover that specific supply. Professional work, testing, packaging or delivery might affect the total. Even then, the quote would not become a national Semax list price or prove FDA approval and routine insurance coverage.

The NDC phrase for human prescription compounding is not evidence that a particular pharmacy may compound Semax. Eligibility depends on the substance, product, facility and applicable federal and state conditions. FDA also states that unapproved drugs have not undergone agency review for safety, effectiveness and quality, and compounded drugs are not FDA approved

FDA's unapproved-drugs guidance explains why an approval record cannot be replaced by a seller or compounder claim[6]. We found no first-party public Semax quote that could be reported as an official product price. An individual written quote would still need its own regulatory and product verification before it could be described accurately.

Why online prices are excluded

Websites advertise products called Semax as sprays, powders and vials. Those checkout amounts are seller asks, not official medicine prices. The listings can differ in claimed sequence, concentration, container size and intended use. Without a common finished product, averaging them would compare unlike items and produce a number with no regulatory product underneath it.

Vendor certificates do not repair the comparison. A certificate may concern a submitted sample without proving the identity, storage history or chain of custody of the unit offered to a reader. A research-use label also does not turn a consumer-facing health product into an approved medicine. PeptideMethods does not name sellers or publish a vendor range for an unapproved product.

Clinic totals are excluded for the same reason. A package may combine consultation, laboratory work, follow-up and delivery with a claimed product. Without a defined approved pack, the total cannot be separated into a US medicine list price. A higher amount does not prove quality, while a lower amount does not establish value or lawful supply.

There is no defensible monthly Semax cost

A monthly estimate needs a verified product price and a defined regimen. The official records supplied neither. Multiplying an online amount by an assumed frequency would turn a grey-market listing into dosing guidance. It would also hide wastage, concentration and package differences that make the products incomparable.

The official data supports only one result: zero official finished-product prices found, a less satisfying answer than a dollar range but one that preserves the distinction between an absent price record and a free product. That record could change if FDA approves a defined product or an official pricing dataset adds a matching pack.

How to verify a future US price claim

Start with the exact finished product. Ask for its application number, manufacturer, dosage form, strength and package quantity. Confirm the application in Drugs@FDA and check the Orange Book separately. An NDC number alone is insufficient because the directory includes unapproved and unfinished listings.

Then match the same NDC and pack to the dated price source. A Medicaid acquisition-cost record, manufacturer list price, pharmacy cash quote and insurer payment decision answer different questions. Keep the date and unit attached to the amount. If the quote concerns compounding, identify the pharmacy and exact preparation, and treat it as patient-specific rather than a national tariff.

As of 16 November 2026, the official evidence stops before that step. No approved Semax finished product was identified, the eight NDC records were unfinished powders and the 11 November NADAC file contained zero matches. A future price claim should be judged against those same product-identity checks rather than against an online headline.

Medical and regulatory disclaimers

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: This page reflects our understanding of the US regulatory status and official price records as of 16 November 2026. Regulations and records change. Verify with FDA, CMS, the relevant state pharmacy regulator and a licensed pharmacy before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.

Frequently asked

How much does Semax cost in the US?

Zero official US finished-product prices were found on 16 November 2026. This means no approved pack with an official price was identified, not that Semax costs zero dollars.

Does Semax have an FDA list price?

No FDA-approved Semax product was identified in Drugs@FDA or the Orange Book, so there is no approved finished pack to which an FDA-linked US product price can be attached.

Why do Semax NDC records not provide a price?

All eight current records are unfinished bulk-ingredient powders. FDA says NDC assignment does not denote approval or reimbursement eligibility, and the records list quantities rather than prices.

Is there a Medicaid or insurance price for Semax?

The 11 November 2026 NADAC file contained zero Semax matches. That means no official NADAC acquisition-cost record was found; it does not decide every possible private, patient-specific claim.

Can online Semax prices be used to estimate a monthly cost?

Not responsibly. Seller listings do not establish a common approved product, and a monthly estimate would add unsupported assumptions about concentration, use frequency and duration.

Sources

  1. [1]US FDA: Drugs@FDA data files, updated 13 November 2026 and searched on 16 November 2026Tier 1 · primary↩
  2. [2]US FDA: Orange Book data files, searched on 16 November 2026Tier 1 · primary↩
  3. [3]US FDA: National Drug Code DirectoryTier 1 · primary↩
  4. [4]openFDA NDC API: Semax listing data, updated 13 November 2026Tier 1 · primary↩
  5. [5]CMS Medicaid: NADAC 2026 CSV dated 11 November 2026Tier 1 · primary↩
  6. [6]US FDA: Unapproved DrugsTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars